ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,431.60
-0.04%
Dow Jones
38,589.16
-0.15%
US Dollar vs MXN
18.4648
0.00%
Brent Oil
82.275
0.00%
Bitcoin
66,279.64
0.42%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. FibroGen Inc (FGEN)

  7. FibroGen Inc (FGEN) Noticias

FGEN

FibroGen (FGEN)

FibroGen Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:FGEN
FechaHoraFuenteTítuloSímboloCompañía
13/06/202415:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
07/06/202415:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FGENFibroGen Inc
03/06/202415:05GlobeNewswire Inc.FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical TrialsNASDAQ:FGENFibroGen Inc
03/06/202415:02GlobeNewswire Inc.FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid TumorsNASDAQ:FGENFibroGen Inc
03/06/202406:00GlobeNewswire Inc.FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:FGENFibroGen Inc
23/05/202416:05GlobeNewswire Inc.FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical OncologyNASDAQ:FGENFibroGen Inc
07/05/202410:55AllPennyStocks.comTraders Rush To Buy Biotech Following Q1 Earnings BeatNASDAQ:FGENFibroGen Inc
07/05/202406:00GlobeNewswire Inc.FibroGen to Participate in Upcoming Investor ConferencesNASDAQ:FGENFibroGen Inc
06/05/202415:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:FGENFibroGen Inc
06/05/202415:02GlobeNewswire Inc.FibroGen Reports First Quarter 2024 Financial ResultsNASDAQ:FGENFibroGen Inc
29/04/202406:00GlobeNewswire Inc.FibroGen to Report First Quarter 2024 Financial ResultsNASDAQ:FGENFibroGen Inc
24/04/202415:02GlobeNewswire Inc.FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology ANASDAQ:FGENFibroGen Inc
02/04/202416:46GlobeNewswire Inc.FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate CancerNASDAQ:FGENFibroGen Inc
26/03/202406:00GlobeNewswire Inc.FibroGen to Present at 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:FGENFibroGen Inc
11/03/202406:00GlobeNewswire Inc.FibroGen Appoints Deyaa Adib, M.D. as Chief Medical OfficerNASDAQ:FGENFibroGen Inc
26/02/202415:06GlobeNewswire Inc.FibroGen Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:FGENFibroGen Inc
26/02/202415:05GlobeNewswire Inc.FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South KoreaNASDAQ:FGENFibroGen Inc
20/02/202406:00GlobeNewswire Inc.FibroGen to Report Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:FGENFibroGen Inc
14/02/202414:37Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:FGENFibroGen Inc
05/02/202406:00GlobeNewswire Inc.FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024NASDAQ:FGENFibroGen Inc
25/01/202406:00GlobeNewswire Inc.FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic CancerNASDAQ:FGENFibroGen Inc
09/12/202316:02GlobeNewswire Inc.FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual MeetingNASDAQ:FGENFibroGen Inc
06/11/202315:01GlobeNewswire Inc.FibroGen Reports Third Quarter 2023 Financial ResultsNASDAQ:FGENFibroGen Inc
23/10/202306:00GlobeNewswire Inc.FibroGen to Report Third Quarter 2023 Financial ResultsNASDAQ:FGENFibroGen Inc
01/09/202316:31Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:FGENFibroGen Inc
29/08/202315:15GlobeNewswire Inc.FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular DystrophyNASDAQ:FGENFibroGen Inc
07/08/202315:22Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:FGENFibroGen Inc
07/08/202315:01GlobeNewswire Inc.FibroGen Reports Second Quarter 2023 Financial ResultsNASDAQ:FGENFibroGen Inc
25/07/202306:00GlobeNewswire Inc.FibroGen Announces Leadership TransitionNASDAQ:FGENFibroGen Inc
24/07/202306:00GlobeNewswire Inc.FibroGen to Report Second Quarter 2023 Financial ResultsNASDAQ:FGENFibroGen Inc
 Showing the most relevant articles for your search:NASDAQ:FGEN

Su Consulta Reciente

FX
EURUSD
Euro vs US Dollar
AMEX
SPY
SPDR S&P 500
FX
USDMXN
US Dollar vs MXN
NYSE
JPM
JP Morgan Chase
NASDAQ
GOOGL
Alphabet
USI
USTECH100
US Tech 100
SPI
SP500
S&P 500
NASDAQ
QQQ
Invesco QQQ Trust Series 1
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
XOM
Exxon Mobil
NASDAQ
NVDA
NVIDIA
FX
EURMXN
Euro vs MXN
NYSE
NKE
Nike
AMEX
XLF
Financial Select Sector
CCOM
SILVER
SILVER
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados